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The level of replication and immunogenicity of recombinant parainfluenza virus type 3 (rHPIV3) bearing one, two, or three
gene insertions expressing foreign protective antigens was examined. cDNA-derived recombinant HPIV3s bearing genes
encoding the open reading frames (ORFs) of the hemagglutinin-neuraminidase (HN) of HPIV1, the HN of HPIV2, or the
hemagglutinin (HA) of measles virus replicated efficiently in vitro, including the largest recombinant, which had three gene
unit insertions and which was almost 23 kb in length, 50% longer than unmodified HPIV3. Several viruses were recovered
from cDNAs whose genome length was not a multiple of six nucleotides and these contained nucleotide insertions that
corrected the length to be a multiple of 6, confirming that the “rule of six” applies to HPIV3. Using a hemagglutination inhibition
assay, we determined that the HPIV1 HN expressed by recombinant HPIV3 was incorporated into HPIV3 virions, whereas
using this assay incorporation of the HPIV2 HN could not be detected. HPIV3 virions bearing HPIV1 HN were not neutralized
by HPIV1 antiserum but were readily neutralized by antibodies to the HPIV3 HN or fusion protein (F). Viruses with inserts
were restricted for replication in the respiratory tract of hamsters, and the level of restriction was a function of the total
number of genes inserted, the nature of the insert, and the position of the inserted gene in the gene order. A single insert
of HPIV2 HN or measles virus HA reduced the in vivo replication of rHPIV3 up to 25-fold, whereas the HPIV1 HN insert
decreased replication almost 1000-fold. This indicates that the HPIV1 HN insert has an attenuating effect in addition to that
of the extra gene insert itself, presumably because it is incorporated into the virus particle. Viruses containing two inserts
were generally more attenuated than those with a single insert, and viruses with three inserts were over-attenuated for
replication in hamsters. Inserts between the N and P genes were slightly more attenuating than those between the P and the
M genes. A recombinant HPIV3 bearing both the HPIV1 and the HPIV2 HN genes (r1HN 2HN) was attenuated, immunogenic,
and protected immunized hamsters from challenge with HPIV1, HPIV2, and HPIV3. Thus, it is possible to use a single HPIVINTRODUCTION
Several viruses of the order Mononegavirales (Mono-
negaviruses), which are the single-stranded negative-
sense RNA enveloped viruses (Chanock et al., 2001), are
being explored for use as vectors for the expression of
foreign antigens. A foreign open reading frame (ORF) that
is placed under the control of viral gene-start (GS) and
gene-end (GE) transcription signals and inserted into the
gene order is transcribed as a separate mRNA. In gen-
eral, the foreign protein is expressed efficiently in vitro
and in vivo, and the foreign insert is maintained stably
through multiple passages, making the mononegavi-
ruses attractive candidates as vaccine vectors (Bukreyev
et al., 1996; Durbin et al., 2000; He et al., 1997; Mebatsion
et al., 1996; Schnell et al., 1996b; Singh et al., 1999).
Human parainfluenza virus type 3 (HPIV3), a member
of the Paramyxovirinae subfamily of the Paramyxoviridae
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136family in the order Mononegaviruses, is a significant
cause of respiratory tract disease in human infants and
young children and is the focus of an active vaccine
development effort (Crowe, 1995). HPIV3 is also being
actively studied for use as a vaccine vector for the pro-
tective antigens of other viral pathogens, e.g., HPIV2,
respiratory syncytial virus (RSV), and measles virus
(Durbin et al., 2000; Schmidt et al., 2001; Skiadopoulos et
al., 2001; Tao et al., 2001). This strategy consists of
converting a live-attenuated HPIV3 vaccine virus into a
multivalent vaccine virus vector that expresses the pro-
tective antigens of other pediatric pathogens.
The proteins and cis-acting genomic sequences of
HPIV3 are well described, facilitating its use as a vector.
The gene order is as follows: 3 leader-N-P-M-F-HN-L-5
trailer, with the major viral proteins being the nucleocap-
sid (N), phosphoprotein (P), membrane (M), fusion (F),
hemagglutinin-neuraminidase (HN), and the large (L)
polymerase. The 3 and 5 ends of the HPIV3 genome
contain extragenic leader and trailer regions, and the 3
end of the genome contains the promoter for replicationvector expressing two foreign gene inserts to protect infa
disease caused by the three major human PIV pathogens.
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and transcription (Chanock et al., 2001). One novel fea-nts an
© 200
ture of the PIVs and other members of subfamily
Paramyxovirinae is that the genome length needs to be a
multiple of six nucleotides for efficient replication (Calain
and Roux, 1993; Durbin et al., 1997b). Transcription ini-
tiates at the 3 end and proceeds by a sequential stop–
start mechanism that is guided by short conserved mo-
tifs found at the gene boundaries. The upstream end of
each gene contains a 10-nucleotide GS signal, which
directs transcription initiation of its respective mRNA.
The downstream terminus of each gene contains a 12-
nucleotide GE signal that directs transcription termina-
tion and polyadenylation, and each gene is separated by
a conserved intergenic trinucleotide that also is thought
to play a role in transcription.
We have previously demonstrated that live-attenuated
recombinant PIV3 vectors expressing the protective an-
tigens of measles or RSV can be used as live-attenuated
multivalent vaccines to induce protective immune re-
sponses in rodents and primates (Durbin et al., 2000;
Schmidt et al., 2001; Skiadopoulos et al., 2001). Further-
more, viable recombinant antigenic chimeric HPIV3s
bearing the HPIV1 F and HN (rHPIV3-1) or the HPIV2 F
and HN antigenic determinants (rHPIV3-2) in place of
their HPIV3 counterpart glycoproteins have been con-
structed and can be used to boost an immune response
to a foreign antigen after the initial immunization with an
HPIV3 vector (Skiadopoulos et al., 1999b; Tao et al.,
2000b). A chimeric rHPIV3-1 bearing the HPIV2 HN gene
inserted between the F and HN genes (rHPIV3-1.2HN)
was immunogenic and protected hamsters from chal-
lenge with HPIV2 and HPIV1 (Tao et al., 2001). Thus,
recombinant live-attenuated PIV vaccine vectors can be
used to immunize against disease caused by HPIV1,
HPIV2, and HPIV3, for which there is an independent
need for a vaccine, as well as against additional viral
pathogens.
We previously showed that HPIV3 can accommodate
foreign noncoding sequences of various lengths either
as mRNA-encoding gene units (GU) inserted between
the HPIV3 HN and L genes or as insertions that in-
creased the length of the 3-noncoding region (NCR) of
the HN gene but that did not change the number of
encoded mRNAs. Viruses bearing GU and NCR inser-
tions of up to 3.9 kb were readily recovered and, in the
case of the longer inserts, were moderately attenuated in
the respiratory tract of hamsters (Skiadopoulos et al.,
2000). In other studies, attenuated HPIV3s bearing the
measles virus hemagglutinin (HA) gene inserted be-
tween the N-P, P-M, or HN-L genes induced a strong
measles virus HA specific immune response in hamsters
or primates, with the insert in the 3 promoter proximal
N-P and P-M locations being more immunogenic in vivo
than in the HN-L junction (Durbin et al., 2000; Skiado-
poulos et al., 2001).
In the present study, we further explored the useful-
ness of HPIV3 as a vector for the expression of other
paramyxovirus protective antigens. Three basic ques-
tions were addressed. First, what is the effect of expres-
sion of one, two, or three separate gene inserts on the
level of replication, immunogenicity, and genetic stability
of a recombinant HPIV3 wild-type (wt) virus? Second,
what is the effect of the site of insertion on the level of
replication and immunogenicity of the recombinant vac-
cine virus? Third, does the nature of the foreign gene
insert (i.e., the HA of measles virus or the HN of HPIV1 or
HPIV2) affect the ability of the vector to replicate and to
induce an immune response? It was found that each of
these factors made an independent contribution to the
replication of the HPIV3 vector in vivo and thus are
important elements to be considered in the design of an
effective multivalent parainfluenza virus vaccine.
RESULTS
Recovery and in vitro replication of recombinant
HPIV3s bearing single or multiple gene inserts
Eleven HPIV3 antigenomic cDNAs were constructed
containing one, two, or three gene insertions from the
following list: (i) the HN of HPIV1 wt (1HN); (ii) the HN of
HPIV2 wt (2HN); (iii) the HA of measles virus (HA); and (iv)
a 3918-nt translationally silent synthetic gene unit called
GU3918. The GU3918 insert was included to examine the
upper limit of HPIV3 genome size that could be recov-
ered from cDNA. The added genes were inserted into
rHPIV3 wt between the N and P genes (N-P), between
the P and M genes (P-M), or between the HN and L
genes (HN-L). In all cases, each insert was placed under
the control of HPIV3 cis-acting GS and GE transcription
signals such that each would be expressed as a sepa-
rate mRNA (Figs. 1 and 2).
Due to an error in construction, six of the eight anti-
genomic cDNAs containing the HPIV2 HN insert did not
conform to the rule of six. Recombinant virus was recov-
ered readily from each of the antigenomic cDNAs includ-
ing those that did not conform to the rule of six and these
are indicated with asterisks: r2HN*N-P (#3), r2HN*P-M (#4),
r1HN2HN* (#6), r2HN*HA (#9), r1HN2HN*HA (#10), and
r1HN 2HN* GU3918 (#11), (Fig. 2). As described below, two
of the inserted ORFs (contained in r1HNHA (#8) and
r2HN*HA (#9)) failed to express an antigenically active
protein; each antigenically silent insert is indicated with
italics. All recovered recombinant HPIV3s bearing single
or multiple gene inserts replicated to high titer in vitro
(Fig. 2).
Several recombinants, especially those with multiple
insertions, were restricted in replication at 39°C, as seen
previously for single large gene unit insertions in HPIV3
(Skiadopoulos et al., 2000). It is noteworthy that one
construct, r1HN2HN*HA (#10) (see Fig. 2), contained the
protective antigens for four pathogens: HPIV3 (HN and
F), HPIV1 (HN), HPIV2 (HN), and measles virus (HA). The
total length of foreign sequence inserted into this recom-
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binant was about 5.5 kb, which is 36% of the total HPIV3
genome length of 15,462 nt. The largest recombinant,
r1HN 2HN*GU3918 (#11) (Fig. 2), was approximately 23 kb
in length, which is 50% longer than wild-type HPIV3.
Sequence analysis of recovered viruses
The recovered viruses were sequenced to address
two issues. First, it was unexpected to be able to effi-
ciently recover virus from cDNAs that violated the rule of
six, and it was of interest to determine the sequence of
the recovered viruses to establish whether a correction
to conform the genome to the rule of six had occurred.
Second, it was of interest to determine whether the
foreign ORFs were recovered and maintained in the
recombinant virus in an intact form.
Analysis of the complete sequences of the genomic
RNAs of r2HN*N-P (#3) and r2HN*P-M (#4) showed that
each contained a single U nucleotide insertion (genome
sense) that modified the genome length of each virus to
conform to the rule of six. In each case, this insertion
occurred within the poly(U) tract (genome-sense) of a GE
signal sequence. In the case of r2HN*N-P (#3), this oc-
curred in the N GE signal immediately upstream of the
HPIV2 HN insert, and in the case of r2HN*P-M (#4) in the
P GE signal, which also was immediately upstream of
the HPIV2 HN insert (Figs. 1 and 2, Table 1). Each single
nucleotide insertion within the GE polyadenylation signal
(poly(U) tract) altered the U5 tract to U6. Since the GE
poly(U) tracts in HPIV3 vary in length (U5 or U6), we
considered these viruses bearing single nucleotide in-
sertions in the GE suitable for further biological evalua-
tion, and the in vitro and in vivo levels of replication
suggest that modification of this poly(U) tract had a
minimal effect on replication (see below).
Three of the other viruses recovered from antigenomic
cDNAs that violated the rule of six (r1HN2HN* (#6),
r2HN*HA (#9), and r1HN2HN*GU3918 (#11)) also con-
tained a single nucleotide insertion that could potentially
modify the genome length to conform to the rule of six
(Table 1), but the entire genome of these three viruses
was not sequenced. The relative locations of these sin-
gle nucleotide insertions are indicated in Fig. 2 by single
arrows. In the cases of r1HN2HN* (#6) and r2HN*HA
(#9), the insertions occurred within a poly(U) tract in the
HPIV1 HN ORF or in a poly(A) tract within the HPIV2 HN
ORF insert, respectively (Table 1), and the consequence
of these changes for expression of these ORFs is de-
scribed below. In the case of r1HN2HN* GU3918 (#11), the
modification involved a single U insert in the poly(U) tract
of the GE signal of the HPIV1 HN insert (Table 1). For
r1HN2HN*HA (#10), insertions were not detected in the
HPIV1 HN and HPIV2 HN ORFs, their flanking se-
quences, or the flanking sequences of the HA insert, but
the entire genome was not sequenced.
Of the 18 inserts that were sequenced completely, 11
lacked any mutations in the ORF or flanking regions.
FIG. 1. Structure of the cloning site used to insert the HPIV1 and HPIV2 HN glycoprotein ORFs between the HPIV3 P and M genes. The downstream
(3 with respect to the antigenome) NCR of the HPIV3 P gene was previously modified to contain an AflII restriction site at antigenomic positions
3693–3698, which was then used to introduce an oligonucleotide duplex specifying HPIV3 cis-acting transcriptional signal sequences, i.e., gene end
(GE), intergenic (IG), and gene-start (GS) signal sequences, as indicated. The specific GS sequence was that of the N, P, and M genes, and the specific
GE sequence was that of the N and P genes. The HPIV1 or HPIV2 HN ORF was introduced into the NcoI–HindIII restriction sites. As illustrated, this
arrangement placed the inserted ORF under the control of a separate set of GS and GE signals, such that it was expressed as a separate mRNA.
A short oligonucleotide duplex was inserted into the MluI site of the multiple cloning site to adjust the total length of the genome to be a multiple
of 6. A similar cloning site and strategy was used to introduce the HPIV1 or HPIV2 HN ORF between the HPIV3 N and P genes at an introduced AflII
site at nts 1677–1682.
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These included each of the three gene insertions con-
taining the measles virus HA (r1HNHA (#8), r2HN*HA
(#9), and r1HN2HN*HA (#10)). Three other recombinants
lacked mutations in the ORFs but had mutations in non-
coding regions that corrected the deviation from the rule
of six (r2HN*N-P (#3), r2HN*P-M (#4), r1HN2HN*GU3918
(#11)). Thus, 14 of 18 (78%) ORFs were intact, whereas
the other four had mutation(s) that altered the sequence
of the ORF (r1HN2HN* (#6), r1HNHA (#8), r2HN*HA (#9),
r1HN2HN*GU3918 (#11)). In each of the five recovered
viruses containing only one gene insertion (i.e., virus
#1–5, Fig. 2), the ORF remained intact.
Three of seven (43%) HPIV1 HN ORF insertions con-
tained a mutation in the HPIV1 HN ORF (Table 1). Spe-
cifically, one of the recovered viruses (r1HNHA (#8))
contained 95 A to G substitutions (genome sense) that
occurred within a 1054-nt stretch of the HPIV1 HN ORF at
the location indicated in Fig. 2. These 95 biased hyper-
mutations also resulted in 56 amino acid substitutions in
the 575 amino acid HPIV1 HN protein. These changes
occurred between amino acid positions 21 and 361 of the
HPIV1 HN protein and involved the cytoplasmic tail, the
transmembrane region, and approximately the first 300
amino acids of the ectodomain. This virus did not ex-
press an antigenic HPIV1 HN protein detectable by indi-
rect immunofluorescence (see below). Biased hypermu-
tation was also observed in the HPIV1 HN ORF of an
additional clone of r1HN2HN (data not shown). The hy-
permutated version of r1HN2HN was not further charac-
terized. A r1HN2HN (#7) without mutations in the HPIV1
and HPIV2 HN ORFs was used for further characteriza-
tion. A second virus, r1HN2HN* (#6), contained a single
nucleotide (U) inserted after nucleotide 15 of the HPIV1
HN ORF. This insertion corrected the rule of six, as
mentioned above, but would have resulted in a shift in
the reading frame following HPIV1 HN amino acid posi-
tion 5 into a second frame that was open for only three
codons. This frameshift might have been expected to
preclude expression of a full-length HPIV1 HN protein.
Surprisingly, however, this virus expressed an HPIV1 HN
protein detectable by indirect immunofluorescence, HAI
assay, and immunogenicity in vivo (see below). One
possibility is that, in this frame-shifted HPIV1 HN insert,
translation can initiate at a second AUG codon corre-
sponding to position 43 in the amino acid sequence to
produce an N-terminally truncated HN protein. However,
this has not been confirmed directly.
The nt sequence of the HPIV2 HN ORFs of seven of
eight viruses with an HPIV2 HN insert was intact. One
virus, r2HN*HA (#9), contained a single nucleotide inser-
tion (A) within a stretch of four consecutive A residues
(genome sense) in its HPIV2 HN ORF that corrected the
FIG. 2. Schematic representation of recombinant HPIV3 with single or multiple gene insertions. Diagram (not to scale) of the genome structure of
a series of recombinant HPIV3s with one, two, or three gene inserts, containing the HPIV1 HN ( ), HPIV2 HN ( ), measles virus HA ( ), or a 3918-nt
gene unit insert (GU3918) that does not encode a protein (p). Each foreign insert is under the control of a set of HPIV3 GS and GE transcription signals
and is expressed as a separate mRNA. Each rHPIV3 bearing an additional ORF is also designated by a construct number here and throughout the
text to facilitate identification. The ORFs that are designated in italics are those which sustained point mutations during replication that preclude
expression of an antigenic polypeptide. Recombinants with the HPIV2 HN ORF insert designated 2HN* were generated from cDNAs that did not
conform to the rule of six (i.e., they were 6n  5 in length). Single nucleotide insertions (2) are indicated. The relative location of the biased
hypermutations consisting of 95 A to G substitutions (222222) is shown. a The predicted genome length for each recovered virus is indicated.
For the rHPIV3 wt, r2HN*N-P (#3), and r2HN*P-M (#4) the indicated genome length was directly determined by sequencing the entire genome. For
r1HN2HN* (#6), r2HN*HA (#9), r1HN2HN* (#10), and r1HN2HNGU3918 (#11) the predicted genome length includes an additional nontemplated
nucleotide insertion which would serve to correct the genome length to conform to the rule of six. b Mean peak titer of virus grown in LLC-MK2 cells
infected at an m.o.i. of 0.01 at 32°C for 7 days. c Virus titer was determined by serial 10-fold dilution on LLC-MK2 cells at 32°C and at 39°C (see
Materials and Methods).
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deviation from the rule of six and that would also have
resulted in a frameshift following amino acid 215 of the
encoded protein. This would have resulted in deletion of
the carboxyl-terminal two-thirds of the HPIV2 HN protein.
This virus did not express an antigenic HPIV2 HN protein
(see below).
Expression of the proteins encoded by the additional
genes inserted into HPIV3
The expression of the foreign antigens from rHPIV3s
was determined on virus-infected LLC-MK2 cells by in-
direct immunofluorescence with polyclonal or monoclo-
nal antibodies specific for HPIV1, HPIV2, or measles
virus (Fig. 3). Two of the recombinants indicated in Fig. 2
(r1HNHA (#8) and r2HN*HA (#9)) failed to express an
antigenically active form of the insert HN protein (data
not shown). However, both of these recombinants ex-
pressed the measles virus HA (Fig. 3C). Presumably, the
mutations sustained by the HN ORFs of these two vi-
ruses (Table 1), namely the 56 amino acid substitutions
due to hyperbiased mutation in the case of r1HNHA (#8)
and the frameshift that deleted the carboxyl-terminal
two-thirds of the protein in the case of r2HN*HA (#9),
precluded expression of the HN protein. Surprisingly, the
nucleotide insertion within the HPIV1 HN ORF of
r1HN2HN* (#6) did not result in ablation of expression of
its protein product (Fig. 3A), which might reflect initiation
at the second AUG codon in the ORF as suggested
above. In the case of r1HN2HN*HA (#10), confirmation of
the expression of the HPIV1 and HPIV2 HN and the
measles virus HA (Figs. 3A, 3B, and 3C) demonstrated
that up to three additional genes can be expressed by a
rHPIV3 vector.
The HPIV1 HN glycoprotein expressed by rHPIV3 is
incorporated into the virus envelope
The PIV HN attachment protein is present on the virus
surface, binds to neuraminic acid containing glycopro-
teins and glycolipids, and can agglutinate erythrocytes
containing these receptors (Coelingh et al., 1986; van
Wyke Coelingh et al., 1987). This hemagglutinating activ-
ity can be specifically inhibited by type-specific antibody.
To determine whether the recombinant HPIV3s express-
ing the HN protein of HPIV1 or HPIV2 incorporated the
foreign glycoprotein into their envelope, antibodies spe-
cific for either HPIV1, HPIV2, or HPIV3 were tested for
TABLE 1
Sequencing Information on Recombinant HPIV3s Containing One, Two, or Three Gene Insertions
Virus
Sequencing information
HPIV1 HNa HPIV2 HNa MV HAa
r1HNN-P (#1) ORF intact NA
b NA
r1HNP-M (#2) ORF intact NA NA
r2HN*N-P (#3)




c,d NA 1-nt insertion (U) into upstream poly(U) tract,e
ORF intact
NA
r2HNP-M (#5) NA ORF intact NA
r1HN2HN* (#6)c,f 1-nt insertion (U) after nt 15 of ORFe,f ORF intact NA
r1HN2HN (#7) ORF intact ORF intact NA
r1HN HA (#8)g ORF contains 95 A to G changes within nts 26–1080 NA ORF intact
r2HN*HA (#9)c,h NA ORF contains 1-nt insertion (A) after nt 644e,h ORF intact
r1HN2HN*HA (#10)c ORF intact ORF intact ORF intact
r1HN2HN*GU3918 (#11)
c, j 1-nt insertion (U) into downstream poly(U) tract,e
Tyr-530 to His i
ORF intact NA
a The entire inserted gene including the ORF and the flanking transcription GE and GS signal sequences was sequenced. Sequence changes are
indicated in genome sense.
b NA, not applicable, recombinant does not contain indicated ORF.
c The antigenomic cDNA used to recover virus did not conform to the rule of six; the cDNA length was 6n  5.
d The entire viral genome sequence was determined.
e Mutations that would serve to correct the genome length to conform to the rule of six are underlined.
f The single nt insertion in the HPIV1 HN ORF resulted in a reading frame shift, but an expression of an antigenically active HPIV1 HN protein
occurred, probably by translational initiation at the second methionyl codon in the ORF to yield an HN protein missing the first 42 amino acids (see
text).
g Hypermutation likely due to a cellular adenosine deaminase.
h The nucleotide insertion results in a reading frame shift that would delete the C-terminal two-thirds of the polypeptide.
i The nucleotide change in this codon was TAC to CAC.
j The GU3918 insert was sequenced only at the gene junctions.
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their ability to inhibit the hemagglutinating activity of the
rHPIVs. As expected, antibodies to HPIV1, HPIV2, or
HPIV3 exhibited type-specific HAI and neutralizing activ-
ity (Table 2) against their respective wild-type virus
(Chanock et al., 2001).
Hemagglutination by each of three rHPIV3s expressing a
full-length HN protein of HPIV1 (r1HNN-P (#1), r1HNP-M (#2),
and r1HN2HN (#7)) was readily inhibited by HPIV1 antibod-
ies, indicating that the HPIV1 HN glycoprotein is incorpo-
rated into the envelope of these HPIV3 vectors (Table 2).
Unexpectedly, hemagglutination by each of these viruses
was not inhibited by HPIV3-specific antibodies. This sug-
gested that the HPIV1 HN is the predominant hemaggluti-
nating glycoprotein in these virus particles. Despite the
presence of the HPIV1 HN in r1HNN-P (#1), r1HNP-M (#2), and
r1HN2HN (#7) virions, HPIV1-specific antibodies did not
neutralize their infectivity, but HPIV3-specific antibodies did
(Table 2), suggesting that the HPIV1 HN protein is not
required for infectivity.
In contrast, hemagglutination mediated by a fourth
virus containing the HPIV1 HN insert, namely r1HN2HN*
(#6), was not inhibited by either HPIV1 or HPIV3 antibod-
ies alone. However, a mixture of HPIV1 and HPIV3 anti-
bodies did inhibit the hemagglutinating activity of
FIG. 3. In vitro expression of the HN or HA gene of HPIV1, HPIV2, or measles virus from recombinant HPIV3s. Indirect immunofluorescence of
LLC-MK2 cells infected with the indicated virus and probed with (A) rabbit polyclonal HPIV1 antibodies; (B) mouse monoclonal HPIV2 HN antibodies;
or (C) mouse monoclonal measles virus HA antibodies.
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r1HN2HN* (#6) (Table 3). Thus, the HPIV3 and HPIV1 HN
proteins present on the r1HN2HN* (#6) virus particle can
independently mediate hemagglutination.
In contrast to rHPIV3s expressing the HPIV1 HN de-
scribed above, the hemagglutination activity of recombi-
nants expressing the HPIV2 HN protein was not inhibited
by HPIV2 antibodies (Table 2). This indicated either that
the HN of HPIV2 was not incorporated into the virion
envelope or, alternatively, that it is not present in a
sufficient quantity in the envelope to mediate erythrocyte
agglutination.
Replication of rHPIV3s expressing one, two, or three
foreign protective antigens in the respiratory
tract of hamsters
It was previously shown that recombinant PIVs ex-
pressing one viral protective antigen replicated effi-
ciently in vitro and in vivo and induced a protective
immune response against both the vector virus antigens
and the inserted gene antigen (Durbin et al., 2000;
Schmidt et al., 2001; Skiadopoulos et al., 2001; Tao et al.,
2001). However, it remained uncertain whether a rHPIV3
with two or three additional foreign antigen genes could
replicate in vivo and induce protective immune re-
sponses against the HPIV3 vector itself and against
wild-type viruses that served as the source of the foreign
antigens. To determine the level of replication in vivo,
hamsters in groups of eight were inoculated intranasally
with 106 TCID50 of a rHPIV3 listed in Fig. 2 or with a
control virus (Table 4).
It was shown previously that a rHPIV3 expressing the
measles virus HA ORF from a gene insert between the
HPIV3 HN and L genes (rHAHN-L), between the N and P
genes (rHAN-P), or between the P and M genes (rHAP-M)
was modestly (about 10- to 20-fold) restricted in replica-
tion in the upper and lower respiratory tract of hamsters
(Durbin et al., 2000). These viruses were reexamined in
parallel with the viruses containing single HPIV1 or
HPIV2 HN ORF inserts to compare the relative levels of
replication in vivo. The approximately 10-fold restriction
of replication of the rHA viruses was confirmed in the
TABLE 2
The HPIV1 HN Is Incorporated into HPIV3 Virions
Virus
Reciprocal neutralization (neut) and HAI antibody titers using antibodies to the indicated virusa:
HPIV1b HPIV2c HPIV3d HPIV3
Neut HAI Neut HAI Neut HAI Neute Neut f
HPIV1 2048 256 ND 4 20 4 100 50
HPIV2 10 4 2560 32 20 4 100 50
rHPIV3 wt 10 4 10 4 1280 32 3200 6400
r2HN*N-P (#3)
g 10 4 10 4 640 16 ND ND
r2HNP-M (#4)
g 10 4 10 4 640 32 ND ND
r1HNN-P (#1) 10 64 10 4 320 4 1200 4800
r1HNP-M (#2) 10 32 10 4 640 4 600 2400
r1HN2HN (#7) 10 32 10 4 960 4 600 6400
r1HN2HN* (#6) 10 4 10 4 960 4 600 4800
a Neutralization was determined by the ability of diluted serum to neutralize infectivity of 100 TCID50 of the indicated virus on LLC-MK2 monolayer
cultures at 32°C. HAI titer was determined by the ability of diluted serum to inhibit hemagglutination of the indicated virus. ND, not determined.
b HPIV1 polyclonal rabbit antibodies.
c HPIV2 polyclonal rabbit antibodies.
d HPIV3 polyclonal rhesus monkey antiserum.
e Mixture of HPIV3 HN monoclonal antibodies (101/1 and 454/11).
f Mixture of HPIV3 F monoclonal antibodies (c265, c145, a640).
g Viruses were tested in a separate assay.
TABLE 3
Antibodies to Both HPIV3 and HPIV1 Are Required to Inhibit
Hemagglutination Mediated by r1HN2HN* (#6)
Virus
HAI titers with antibodies to:
HPIV1a HPIV3b HPIV1  HPIV3c HPIV2d
HPIV1 64 2 64 2
HPIV2 2 2 2 128
rHPIV3 wt 2 128 128 2
r1HNP-M (#2) 8 2 128 2
r1HN2HN* (#6) 2 2 32 2
a HPIV1 polyclonal rabbit antibodies.
b HPIV3 polyclonal rhesus monkey antiserum.
c Mixture of HPIV1 rabbit and HPIV3 monkey antibodies. The amount
of HPIV1 and HPIV3 antibody used was equivalent to the amount used
for HPIV1 or HPIV3 alone.
d HPIV2 polyclonal rabbit antibodies.
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present study (Table 4, groups 6, 7, and 8). Similarly,
insertion of a single gene bearing the HPIV2 HN ORF
also induced a modest reduction (about 10- to 25-fold) in
replication in the respiratory tract of hamsters (Table 4,
groups 3, 4, and 5). Thus, a single gene insert specifies
a modest reduction of replication in both the upper and
the lower respiratory tract of up to 25-fold. In contrast,
insertion of a HPIV1 HN gene resulted in a 100- to
1000-fold reduction of replication in the upper and lower
respiratory tract of hamsters (Table 4, groups 1 and 2).
This suggested that expression of the HPIV1 HN protein
had an additional, specific attenuating effect, possibly
reflecting its incorporation into the virion.
Inspection of the data in Table 4 suggested that the
site of gene insertion might also play a modest role in the
level of restriction of replication of the recombinant virus
in the respiratory tract of hamsters. Insertion of the mea-
sles virus HA ORF between the HPIV3 N and P genes
resulted in a marginally greater reduction of replication
in the upper and lower respiratory tract of hamsters than
did its insertion between the P and M genes (Table 4,
compare group 7 or 8 vs group 6), and these findings
confirm previous results (Durbin et al., 2000). A similar
modest effect was observed with the HPIV2 HN insert,
where insertion between the N and P genes was mar-
ginally more attenuating than between the P and M
genes (compare groups 4 and 5 vs 3), although this effect
was not consistent in the lower respiratory tract of group
5. This insertion site-specific attenuation effect on repli-
cation of the HPIV3 vector was not evident for insertions
of the HPIV1 HN gene, presumably because it was
masked by the more substantial attenuating effect spe-
cific to HPIV1 HN as discussed above.
The recombinant viruses exhibited a gradient of atten-
uation in vivo that was a function of the number of gene
inserts. The viruses bearing three added gene units
exhibited the greatest level of attenuation and were re-
duced over 10,000-fold in replication in the upper and
lower respiratory tract of the infected hamsters (Table 4,
groups 13 and 14). The rHPIV3s bearing two gene inserts
exhibited an intermediate level of attenuation and were
reduced approximately 10- to 1000-fold (Table 4, groups
9–12). rHPIV3s bearing one gene insert (except those
bearing the HPIV1 HN gene) were reduced only approx-
imately 3- to 25-fold (Table 4, groups 3–8). Interestingly,
r1HN2HN* (#6) and r1HN2HN (#7) were not as attenu-
ated for replication in hamsters as rHPIV3s bearing a
single HPIV1 HN insert. The attenuating effect of the
HPIV1 HN may have been reduced by the presence of
the additional HPIV2 HN insert. However, the mechanism
TABLE 4
Replication in the Upper and Lower Respiratory Tract of Hamsters of Recombinant HPIV3s Containing Single or Multiple Gene Inserts
Groupa No. Virusb No. of animals
Mean virus titer (log10 TCID50/g  S.E.)
c in:
Turbinates Titer reduction (log10)
d Lungs Titer reduction (log10)
d
1 r1HNN-P (#1) 8 4.5 0.2 1.9 3.9 0.2 2.7
2 r1HNP-M (#2) 8 3.5 0.2 2.9 4.3 0.2 2.3
3 r2HN*N-P (#3) 8 5.4 0.2 1.0 5.3 0.3 1.3
4 r2HN*P-M (#4) 16 6.2 0.1 0.2 6.2 0.4 0.2
5 r2HNP-M
e (#5) 8 5.9 0.1 0.5 5.2 0.5 1.4
6 rHAN-P 8 5.3 0.2 1.1 5.8 0.4 0.8
7 rHAP-M 8 6.0 0.2 0.4 7.3 0.2 0.7
8 rHAHN-L 8 6.0 0.1 0.4 6.6 0.2 0.0
9 r1HN2HN* (#6) 16 5.1 0.1 1.3 5.1 0.2 1.5
10 r1HN2HNe (#7) 8 5.4 0.1 1.0 4.3 0.2 2.3
11 r1HNHA (#8) 8 3.5 0.2 2.9 3.3 0.1 3.3
12 r2HN*HA (#9) 8 4.7 0.1 1.7 4.9 0.2 1.7
13 r1HN2HN*HA (#10) 8 1.6 0.1 4.8 2.5 0.1 4.1
14 r1HN2HN*GU3918 (#11) 8 2.0 0.2 4.4 1.8 0.2 4.8
15 rcp45 8 4.6 0.1 1.8 2.1 0.2 4.5
16 rHPIV3 wt 24 6.4 0.1 — 6.6 0.1 —
a Groups with 16 or 24 animals are the mean of two or three experiments, respectively.
b Each hamster was inoculated i.n. with 106 TCID50 of virus in a 0.1 ml inoculum.
c Nasal turbinates and lungs were harvested 4 days after inoculation and virus titer was determined.
d Reduction in virus replication compared to rHPIV3 wt (group 16).
e Level of replication was determined in separate experiments.
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by which this reduction in the level of attenuation is
achieved is not known. In general, the level of reduction
of replication specified by the addition of one or more
genes was similar in the upper and the lower respiratory
tract. The most attenuated of these recombinants,
namely those bearing three gene inserts, were substan-
tially more attenuated in the upper respiratory tract than
rcp45 (group 15), a well-characterized and suitably atten-
uated HPIV3 vaccine candidate (Karron et al., 1995; Ski-
adopoulos et al., 1999a).
Immunogenicity in hamsters of rHPIV3s expressing
one or more foreign protective antigens
Hamsters were infected intranasally with HPIV1,
HPIV2, rHPIV3 wt, or with a rHPIV3 bearing one, two, or
three gene inserts as described above. Serum samples
were collected 3 days before immunization and 28 days
postimmunization and were assayed for HPIV1, HPIV2,
HPIV3, or measles virus-specific antibodies by virus neu-
tralization or by HAI (Table 5). All rHPIV3s elicited a
strong immune response to the HPIV3 backbone with the
exception of the viruses bearing the three gene inser-
tions. The reduced or absent HPIV3-specific immune
response in hamsters infected with either the
r1HN2HN*HA (#10) or the r1HN2HN*GU3918 (#11) was likely
a result of these viruses being over-attenuated for replica-
tion in hamsters, since these viruses efficiently expressed
HPIV3 antigens in vitro based on indirect immunofluores-
cence (data not shown). Furthermore, the immune re-
sponse to the vectored antigens in the viruses bearing
three foreign antigens was low or undetectable even
though expression had been confirmed in vitro (Fig. 3).
Viruses bearing one or two foreign gene insertions in-
duced an immune response against each of the additional
antigens. r1HN2HN* (#6) and r1HN2HN (#7) (Table 5;
groups 11 and 12) induced a strong immune response to
HPIV1, HPIV2, and HPIV3. Note that the HPIV1-specific
neutralizing antibody response to r1HN2HN* (#6) (Table 5,
group 11) was equal to or exceeded that of every other virus
that expressed the HPIV1 HN, confirming the finding from
indirect immunofluorescence (Fig. 3) that this virus ex-
presses an antigenically active form of HPIV1 HN despite
the presence of a frameshift early in the ORF. As expected,
r1HNHA (#8) and r2HN*HA (#9) failed to induce an immune
response to the HPIV1 HN and HPIV2 HN glycoproteins,
respectively (Table 5, group 13 and 14).
TABLE 5
Serum Antibody Response in Hamsters to Immunization with rHPIV3 Vectors Expressing Single or Multiple Protective
Antigens of HPIV1, HPIV2, or Measles Virus
Group
No. Virus
Titer reduction (log10) in virus
replication in hamstersa
Antibody response to the indicated virus using
hemagglutination inhibition (HAI) or neutralization (neut) assayb
Turbinates Lungs HPIV3 (HAI) HPIV1 (Neut) HPIV2 (HAI) Measles virus (Neut)
1 rHPIV3 wt 0.0 0.0 10.0 0.0 — — —
2 HPIV2 wt — — 2.0 0.0 — 8.0 0.0 —
3 HPIV1 wt — — 2.0 0.0 4.8 0.3 — —
4 rHAN-P 1.1 0.8 9.5 0.2 — — 12.4 0.4
5 rHAP-M 0.4 0.7 8.7 1.4 — — 11.8 0.2
6 rHAHN-L 0.4 0.0 9.0 0.0 — — 8.1 0.6
7 r1HNN-P (#1) 1.9 2.7 9.5 0.2 3.4 0.6 — —
8 r1HNP-M (#2) 2.9 2.3 7.2 0.8 2.7 0.3 — —
9 r2HN*N-P (#3) 1.0 1.3 9.8 0.5 — 9.3 0.8 —
10 r2HN*P-M (#4) 0.2 0.2 10.0 0.5 — 8.3 1.1 —
11 r1HN2HN* (#6) 1.3 1.5 9.6 0.7 4.8 0.3 8.3 0.8 —
12 r1HN2HN (#7) 1.0 2.3 9.0 0.3 3.8 0.2 10.5 0.4 —
13 r1HNHA (#8) 2.9 3.3 8.3 0.6 2.0 0.0 — 10.8 0.4
14 r2HN*HA (#9) 1.7 1.7 9.8 0.2 — 2.0 0.0 11.1 0.4
15 r1HN2HN*HA (#10) 4.8 4.1 2.0 0.0 2.0 0.0 2.0 0.0 1.0 0.0
16 r1HN2HN*GU3918 (#11) 4.4 4.8 4.3 0.7 2.3 0.6 2.0 0.0 —
17 rcp45 1.8 4.5 7.7 0.2 — — —
a Data from Table 4 shown to facilitate interpretation of immunogenicity.
b Sera were collected 3 days before and 28 days after infection. Mean antibody titer in groups of hamsters (n  6) inoculated IN with 106 TCID50
rHPIV3s expressing the HN protein of HPIV1, HPIV2, or the measles virus HA protein determined by endpoint dilution antibody neutralization assay.
Titers are expressed as mean reciprocal log2  standard error. Sera collected 3 days prior to immunization lacked antibody (2) to each virus tested.
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A single rHPIV3 expressing two foreign viral
glycoproteins is useful as a vaccine to induce
protective antibodies against three viruses
To determine whether the immunogenicity induced by
r1HN2HN* (#6) or r1HN2HN (#7) was sufficient to protect
hamsters against challenge with each of the respective
HPIVs, hamsters were infected intranasally either with a
distantly related paramyxovirus (RSV), with control vi-
ruses (HPIV1, HPIV2 or rHPIV3 wt), or with r1HN2HN*
(#6) or r1HN2HN (#7). After 30 days, hamsters from each
group were challenged with HPIV1, HPIV2, or rHPIV3 wt
and the level of protection afforded by previous infection
with each experimental virus was determined. As dem-
onstrated previously (Cook and Chanock, 1963; Ray et
al., 1990; Tao et al., 2000a), heterotypic protection is not
conferred by a single prior infection with any HPIV (Table
6). However, hamsters previously infected with
r1HN2HN* (#6) or r1HN2HN (#7) were protected from
subsequent challenge with HPIV1, HPIV2, and HPIV3.
The level of protection afforded in the upper respiratory
tract by insert-expressed HPIV1 or HPIV2 HN was less
than that conferred by infection with HPIV1 wt or HPIV2
wt, which might represent the limitation of immunization
with a single viral antigen compared to the correspond-
ing complete infectious virus. In contrast, the level of
restriction of challenge HPIV3 in animals immunized with
the rHPIV3 vector was equivalent to that conferred by wt
HPIV3 infection, reflecting the presence of all of the
HPIV3 antigens in the rHPIV3 vector.
DISCUSSION
Human parainfluenza viruses expressing heterolo-
gous viral genes are being developed for use as multi-
valent vaccines for immunization against common pedi-
atric viral pathogens. In the present study, several factors
were found to affect the in vivo replication and immuno-
genicity of the rHPIV3 vectors, including the total number
of genes inserted, the nature of the gene inserted, and, to
a lesser extent, the location of the insertion in the gene
order. These studies demonstrated that a single rHPIV3-
based chimeric virus can be used to immunize effectively
and achieve protection against HPIV3 and up to two
additional heterologous pathogens.
The two major factors affecting the level of replication
of rHPIV3s in hamsters were the number of genes in-
serted into the HPIV3 genome and, in the case of HPIV1
HN, the nature of the insert. rHPIV3s bearing a single
gene insert of HPIV2 HN or measles virus HA were
reduced in replication from 2- to 25-fold, indicating that a
single gene insert has a small but definite attenuating
effect. In contrast, the HPIV1 HN insert decreased repli-
cation from 100- to 1000-fold. This indicates that the
HPIV1 HN insert has a specific attenuating effect in
addition to that of the extra gene insert itself (discussed
below). The rHPIV3s bearing two gene inserts were re-
duced in replication from 10- to 1000-fold, representing
an incremental increase in attenuation compared to the
single insert vectors containing HPIV2 HN or measles
virus HA. In the case of the double insert viruses, a
further increase in attenuation due to the presence of
HPIV1 HN was not observed, suggesting that this insert-
specific effect was not additive to that of the double
insert. The viruses bearing three inserts exhibited the
greatest level of attenuation and were reduced over
10,000-fold in replication in the upper and lower respira-
tory tract of infected hamsters.
In general, the level of reduction of replication speci-
fied by the addition of one or more genes was similar in
the upper and the lower respiratory tract, which is in
contrast to that of rcp45, a temperature-sensitive (ts)
virus that is more restricted in replication in the warmer
TABLE 6





Mean virus titera (log10 TCID50/ml) to indicated challenge virus:
HPIV1 HPIV2 rHPIV3 wt
Turbinates Lungs Turbinates Lungs Turbinates Lungs
1 RSV 5.3 0.1 5.3 0.2 5.4 0.1 4.2 0.4 6.4 0.1 5.5 0.4
2 HPIV1 1.7 0.2 1.9 0.2 5.4 0.1 4.3 0.5 6.1 0.2 5.1 0.3
3 HPIV2 5.2 0.2 4.9 0.2 1.5 0.0 1.7 0.2 6.1 0.1 5.2 0.5
4 rHPIV3 wt 5.1 0.2 4.9 0.1 5.3 0.1 4.2 0.4 1.7 0.2 1.5 0.0
5 r1HN2HN* (#6) 3.9 0.4 2.1 0.4 3.6 0.4 1.5 0.0 1.6 0.1 1.5 0.0
6 r1HN2HN (#7) 2.6 0.4 2.1 0.3 3.0 0.4 1.9 0.2 1.9 0.2 1.7 0.2
a Hamsters in groups of 6 were immunized with 106 TCID50 of the indicated virus. After 30 days, hamsters were challenged i.n. with 10
6 TCID50 of
the indicated virus. Lungs and nasal turbinates were harvested 4 days later, and virus titer was determined by limiting dilution on LLC-MK2 cells at
32°C.
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lower respiratory tract. The most attenuated of these
recombinants, namely those bearing three additional
genes, were substantially more attenuated in the upper
respiratory tract than rcp45, suggesting that they might
be over-attenuated. These findings demonstrate that
wild-type HPIV3 can be attenuated by the acquisition of
one to three inserts, with the level of attenuation of a
rHPIV3 vector with two inserts being similar in the upper
respiratory tract to that of the HPIV3 cp45, a vaccine
candidate that appears satisfactorily attenuated in hu-
mans (Karron et al., 1995). However, the chimeric viruses
bearing two inserts were less attenuated than HPIV3
cp45 in the lower respiratory tract. If necessary, further
attenuation of the vector for the lower respiratory tract
could be achieved by the transfer of one or more atten-
uating ts mutations, which preferentially restrict replica-
tion in the lower respiratory tract (Skiadopoulos et al.,
1999a).
Interestingly, the addition of foreign inserts had little
attenuating effect on replication in vitro. For example,
viruses containing three additional genes were readily
recovered from cDNA and expressed the three foreign
proteins in cell culture. The largest recovered virus was
23 kb in length, 50% longer than parental HPIV3, but
nonetheless it replicated to high titer in vitro. Thus, there
is a significant dissociation between the ability of a virus
bearing two or three gene inserts to replicate in vitro (not
significantly restricted) and in vivo (10- to 70,000-fold
restricted). Clearly, the cells of the intact host provide a
more stringent environment for virus replication than do
cells in tissue culture. Efficient replication in vitro is an
important requirement for a vaccine virus, particularly
because the attenuated nature of such viruses some-
times requires a higher dose for effective immunization.
It was, therefore, encouraging to note the small effect
gene insertion had on in vitro replication of HPIV3.
The immunogenicity of the HPIV3 vector and the insert
antigens was, in part, influenced by their level of repli-
cation in vivo. rHPIV3 vectors with one or two inserts
induced levels of serum antibodies in hamsters that
were equivalent to, or only slightly less than, those in-
duced by infection with wild-type virus. In these in-
stances the reduction in replication imposed by the in-
sert was not reflected in a reduction of its immunogenic-
ity. In contrast, recombinants with three inserts, which
expressed the vectored antigens in vitro but replicated to
a very low level in vivo, were poorly immunogenic in vivo
and thus were over-attenuated for hamsters.
HPIV3 vectors expressing both the HPIV1 and the
HPIV2 HN glycoproteins protected hamsters from sub-
sequent challenge with HPIV1, HPIV2, and HPIV3. Thus,
the immune response to vectors with two inserts was
sufficient to protect against challenge with each of the
three major disease-causing HPIVs. However, the level
of resistance to replication of HPIV1 or HPIV2 challenge
virus afforded by the HPIV1 and HPIV2 HN insert anti-
gens, respectively, was less in the upper respiratory tract
than that conferred by infection with the homologous
wild-type virus, despite the induction of a comparable
level of serum antibodies to the HN insert. This suggests
that other immune factors, either antibodies to the F
protein or T cell mediated immunity to the other viral
proteins, contribute to the restriction of replication of
HPIV1 and HPIV2 challenge virus in the upper respira-
tory tract of the hamster. This illustrates a limitation of a
strategy that depends upon immunization with a single
protective antigen. An alternative strategy would be to
develop a bivalent virus expressing both the HN and the
F of a heterologous HPIV, a strategy that thus includes
both neutralization antigens.
As indicated above, the HPIV1 HN insert has an atten-
uating effect in addition to that of the extra gene insert
itself. Since the HPIV1 HN, HPIV2 HN, and measles virus
HA gene insertions are all approximately the same size
(1794, 1782, and 1926 nt, respectively), the greater reduc-
tion of replication of rHPIV3s bearing an HPIV1 HN insert
was unlikely a function of insert length. The additional
attenuation conferred by the HPIV1 HN gene might be a
consequence of its incorporation into the virion in
amounts sufficient to mediate hemagglutination, in con-
trast to the HPIV2 HN, which was not incorporated at
such levels, if at all. Indeed, the hemagglutinating activity
of virions expressing the full-length HPIV1 HN was in-
hibited by HPIV1 antibodies alone, but not by HPIV3
antibodies alone, indicating that the HPIV1 HN was the
predominant HN on the surface of the virion. Since the
HPIV1 HN was present in the gene order in a more
promoter proximal location than that of the HPIV3 HN for
each of the HPIV3 vectors, it is likely that it was ex-
pressed at a higher level (Durbin et al., 2000; Schmidt et
al., 2002), and more of it was available for incorporation
into virions than the HN of HPIV3.
The incorporation of HPIV1 HN into HPIV3 particles is
consistent with previous observations that the HPIV1 F
and HN glycoproteins, but not those of HPIV2, could
replace their HPIV3 counterparts in a recombinant anti-
genic chimeric virus (Tao et al., 1998, 2000b). This ap-
parent compatibility between HPIV3 and HPIV1 likely is a
reflection of the closer taxonomic relationship between
HPIV1 and HPIV3 as compared to HPIV2 and HPIV3.
Chimeric HPIV3s containing the HPIV2 F and HN glyco-
proteins in place of those of HPIV3 could be recovered
only if the cytoplasmic tail of HPIV2 F and HN was
replaced with that of HPIV3 F and HN, respectively (Tao
et al., 2000b). This finding identified the important role
played by the cytoplasmic tail of HN or F of HPIV3 in
incorporation into HPIV3 virions. This contrasts with the
situation for VSV, where envelope glycoproteins from
distantly related viruses such as measles virus or RSV
were readily incorporated into the VSV envelope in most
instances (Schnell et al., 1996a).
Although the HPIV1 HN was incorporated into the
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HPIV3 envelope and was functional in hemagglutination,
the virions were not neutralized by HPIV1 antibodies. In
contrast, they were readily neutralized by HPIV3 antibod-
ies specific for either the HPIV3 HN or the F glycoprotein.
This confirmed that the endogenous HPIV3 glycoproteins
mediate infectivity. Similarly, VSV expressing the mea-
sles virus HA protein or the RSV G or F glycoprotein
incorporate the foreign protein into the VSV envelope, but
the infectivity of these viruses is not neutralized by mea-
sles or RSV antibodies (Kahn et al., 2001; Schlereth et al.,
2000). Since PIVs generally require the HN and F to
come from the homologous virus to mediate viral entry
(Tong and Compans, 1999), the HPIV1 HN protein in the
HPIV3 virions most likely is not required for infectivity
and is present only as a passenger. However, its pres-
ence in the virion might interfere with the efficient asso-
ciation of the HPIV3 HN and F glycoproteins required for
successful viral penetration (Tanaka et al., 1996; Tong
and Compans, 1999; Yao et al., 1997). This might occur by
some specific interaction such as the formation of mixed
oligomers of HPIV1 and HPIV3 HN proteins, which might
not function efficiently, or by an association of the HPIV1
HN with the HPIV3 F in a manner that does not mediate
infection but ties up HPIV3 F. Alternatively, it might reflect
some less specific effect such as crowding and diluting
out the HPIV3 HN spikes in the envelope by HPIV1 HN
spikes. Whatever the specific mechanism, we suggest
that this interference is responsible for the increased
attenuation observed in vivo for HPIV3 viruses bearing
the HPIV1 HN insert.
It also is interesting to note that the HPIV1 HN insert
acquired mutations somewhat more frequently than the
HPIV2 HN or measles virus HA inserts, suggesting that
there might be a selective pressure for inactivating ex-
pression of the HPIV1 HN. In addition to the r1HNHA
(#8), another clone of r1HN2HN that was not further
studied also exhibited hyperbiased mutation that elimi-
nated the expression of an antigenically active HPIV1 HN
protein (data not shown). The hyperbiased mutations
observed in the r1HNHA (#8) HPIV1 HN insert involved
multiple (95) nucleotide substitutions of A residues to G.
These mutations likely resulted from the enzymatic ac-
tivity of RNA adenosine deaminase (Bass, 1997; Samuel,
2001). A third recombinant expressing the HPIV1 HN
(r1HN2HN*) contained a nucleotide insertion that pre-
sumably resulted in deletion of the cytoplasmic tail and
part of the transmembrane domain.
Modification of the HPIV1 HN ORF was only seen in
HPIV3 vectors with two or more inserts, suggesting that
the more distal location of the HPIV3 HN protein in such
vectors was additionally restrictive for overall replication.
The high frequency of loss of the HPIV1 HN ORF was
unexpected since foreign gene inserts are generally sta-
ble when expressed by mononegavirus vectors
(Bukreyev et al., 1999; Mebatsion et al., 1996; Schnell et
al., 1996a) even after prolonged passage in vitro (Schnell
et al., 1996b; Tao et al., 2001). The HPIV1 HN was mod-
ified in vitro with a higher frequency, most likely because
it decreased replicative efficiency in vitro and selective
pressure favored mutants lacking an intact HN. Similar
findings have been observed for VSV vectors expressing
foreign proteins that have growth-restricting properties.
Recombinant VSVs expressing the F protein of measles
virus or the neuraminidase protein of influenza virus
were attenuated to a greater extent than vectors bearing
other similar size gene insertions, and loss of measles F
expression occurred rapidly upon passage in vitro (Qui-
nones-Kochs et al., 2001; Schnell et al., 1996a).
The apparent selection of vectors that lack an intact
HPIV1 HN ORF suggests that HPIV3 may not be ideally
suited as a vector for unmodified HPIV1 antigens. It is
possible that a gene encoding a secreted form of HPIV1
HN, completely lacking a membrane anchoring domain,
may be immunogenic and better tolerated by an HPIV3
expression vector. Conversely, the findings presented
here suggest that a HPIV2-based vector may also be
suitable for the expression of HPIV1 glycoproteins.
The site of insertion of the foreign ORF also conferred
attenuation in vivo, although to a much smaller degree
than the two factors discussed above. In general, inser-
tion between the N and P gene decreased replication by
about two- to threefold more than insertion between the
P and M or between the HN and L genes. The mecha-
nism of this effect is not understood, but one explanation
may be that the relative molar ratio of the N and P
proteins is important for virus replication. This ratio
would be altered when a gene unit is placed between the
N and P genes because transcription of the more-distal
P gene would be reduced. Single gene insertions before
the N gene do not seem to have such an effect, presum-
ably because the ratio of the vector proteins produced
remains the same (Huang et al., 2001; Schmidt et al.,
2001). Thus, a pre-N ORF insertion site or one between
the P and M genes is preferred for a high level of
expression of the inserted gene in PIV3s. However, in-
sertion of a foreign gene between the N and P genes
may be useful if an additional level of attenuation of the
vector is required.
Each member of Paramyxovirinae that has been fully
sequenced to date has a genome nucleotide length that
is an even multiple of 6. This has been shown to be a
requirement for efficient replication; this “rule of six” is
thought to be a consequence of each N protein subunit
interacting with exactly six nucleotides in the vRNA nu-
cleoprotein (Calain and Roux, 1993; Durbin et al., 1997b;
Kolakofsky et al., 1998). In this study, viruses were readily
recovered from several cDNAs that did not conform to
the rule of six (specifically, each cDNA length was 6n 
5). Complete sequence analysis of two recovered viruses
and partial sequence analysis of three others revealed a
single nucleotide insertion in each instance that would
serve to correct the genome length to conform to the rule
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of six. Interestingly, three of the five recombinants had a
nucleotide insertion within a GE signal sequence, spe-
cifically within the poly(U) tract at the downstream end of
the GE signal that encodes the poly(A) tail. The other two
had an insertion within a poly(A) or a poly(U) tract in the
foreign gene ORF. Clearly HPIV3 genomes prefer to have
a genome length that conforms to the rule of six and can
preferentially use the polyadenylation signal sequence
or other poly(A) or poly(U) tract to correct deviations in
genome length. It was shown previously that Sendai
virus minigenomes underwent in vitro genome length
correction by insertion or deletion of nucleotides exclu-
sively within the P gene editing site (a polypurine tract)
(Hausmann et al., 1996), and it was suggested that the
mRNA editing and genome length correction activities
may be linked. Defective interfering genomes of SV5, a
member of the Rubulavirus genus, generated from
cDNAs that did not conform to the rule of six were found
to contain nontemplated poly(A) insertions that modified
the genome length to conform to the rule of six (Murphy
and Parks, 1997). However, these insertions did not oc-
cur at a poly(A) or poly(U) tract, nor at the P gene editing
site, suggesting that the genome length can be corrected
by a number of different mechanisms.
The data presented here demonstrate that effective
multivalent vaccines against multiple human pathogens
may be generated from recombinant chimeric HPIV3s.
The extraordinary flexibility of the length of the viral
genome as well as the stability of foreign gene insertions
that do not interfere with virus replication underscore the
usefulness of Paramyxoviruses and other Mononegavi-
ruses as expression vectors and as potential vaccines.
MATERIALS AND METHODS
Cell lines and viruses
HEp-2 (ATCC CCL 23) and LLC-MK2 (ATCC CCL 7.1)
cells were maintained in OptiMEM I (Life Technologies,
Gaithersburg, MD) supplemented with 5% FBS and gen-
tamicin sulfate (50 g/mL). The generation and charac-
terization of the recombinant JS strain (GenBank Acces-
sion No. Z11575) of HPIV3 wild-type (rHPIV3 wt), and its
attenuated derivative containing the temperature-sensi-
tive (ts) and attenuating mutations of the cold-passaged
HPIV3 cp45 candidate vaccine virus (rcp45), were de-
scribed previously (Durbin et al., 1997a; Skiadopoulos et
al., 1998). The biologically derived HPIV1 wt (Washing-
ton/1964) and HPIV2 wt (HPIV2/V9412) were described
previously (Tao et al., 1998, 2000b). The recombinant
HPIV3 viruses expressing the HA gene of measles virus
as a single gene unit insertion have been described
previously (Durbin et al., 2000). The HPIVs were propa-
gated in LLC-MK2 cells and were quantified by limiting
dilution with virus-infected cultures identified by hemad-
sorption with guinea pig erythrocytes, as described pre-
viously (Durbin et al., 1997a; Hall et al., 1992; Skiadopou-
los et al., 1998). The biologically derived RSV A2 strain
was grown in HEp-2 cells and was quantified by plaque
assay as described previously (Crowe et al., 1994).
Construction of recombinant HPIV3s with one or
more additional gene units encoding the HPIV1 HN,
HPIV2 HN, or measles virus HA
In previous work (Durbin et al., 2000), plasmid pUC119
(PmlI–BamHI), a subclone of the HPIV3 antigenomic
cDNA that spans from the PmlI site in the N gene to the
BamHI site in the M gene (Durbin et al., 2000), was
modified by site-directed mutagenesis to encode a
unique AflII site in (i) the downstream noncoding region
of the HPIV3 N gene (CTAAAT to CTTAAG, HPIV3 nts
1677–1682; GenBank Accession No. Z11575); or (ii) the
downstream noncoding region of the HPIV3 P gene
(TCAATC to CTTAAG, HPIV3 nts 3693–3698). As de-
scribed previously, each site was used for the insertion
of the measles virus HA ORF flanked by HPIV3 GS and
GE signals (Durbin et al., 2000). For the insertion of the
HPIV1 and HPIV2 HN ORFs, each AflII site was modified
by the insertion of an oligonucleotide duplex, creating
two intermediate plasmids, pUC(GE/GS)N-P and pUC(GE/
GS)P-M. The inserted duplex contained an HPIV3 GE se-
quence, the intergenic (IG) trinucleotide sequence, and
an HPIV3 GS sequence (Fig. 1). Additional unique restric-
tion endonuclease sites were included in the multiple
cloning region to facilitate subsequent subcloning and
screening, including NcoI and HindIII sites for addition of
the HPIV1 or HPIV2 HN ORFs. Thus, a foreign ORF
inserted into the multiple cloning site would be under the
control of a set of HPIV3 transcription signals and would
be expressed as a separate mRNA by the HPIV3 poly-
merase. The multiple cloning site also contained anMluI
site into which an oligonucleotide of the appropriate
length could be inserted as necessary to make the entire
inserted sequence conform to the rule of six (Calain and
Roux, 1993; Durbin et al., 1997b; Skiadopoulos et al.,
2000).
The HPIV3 vector cDNAs containing one insert were
constructed first. The HPIV1 HN ORF, available as a
NcoI–HindIII cloned restriction fragment (Tao et al.,
1998), was inserted into the NcoI–HindIII sites of
pUC(GE/GS)N-P and pUC(GE/GS)P-M to generate pUC
1HNN-P and pUC 1HNP-M, respectively. Short oligonucle-
otide duplexes were inserted in the unique MluI restric-
tion site to adjust the total insert length to conform to the
rule of six. The exact sequence for each construct is
available on request. These chimeric subgenomic
cDNAs were then cloned into the full-length HPIV3 anti-
genomic cDNA p3/7(131)2G, referred to here as
pFLCHPIV3wt, to yield pFLC1HNN-P and pFLC1HNP-M, re-
spectively, and were used to derive recombinant viruses
r1HNN-P (#1) and r1HNP-M (#2) (Fig. 2).
The HPIV2 HN ORF (Tao et al., 1998) was similarly
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inserted as an NcoI–HindIII restriction fragment and
plasmids were similarly assembled and named. How-
ever, for several constructs bearing the HPIV2 HN ORF,
the inserted oligonucleotide duplex used to modify the
construct to conform the length of the insert to the rule of
six was mistakenly designed to be one nucleotide
shorter than necessary. Plasmids and recovered viruses
bearing an HPIV2 HN insertion that did not conform to
the rule of six are denoted by an asterisk (Fig. 2). Viruses
were recovered from these cDNAs and are designated
r2HN*N-P (#3) and r2HN*P-M (#4), respectively (Fig. 2). A
second version of pFLC2HNP-M that conformed to the rule
of six was constructed and used to recover the virus
r2HNP-M (#5) (Fig. 2).
Additional recombinant HPIV3 antigenomic cDNAs
were assembled that contained up to three foreign
genes in various combinations and locations in the
HPIV3 backbone (Fig. 2), using convenient restriction
endonuclease sites. These antigenomic cDNAs were
assembled from the subgenomic cDNAs described
above in which the HN of HPIV1 or HPIV2 was inserted
between the N and P genes or the P and M genes. Other
subclones used for assembly contained the measles
virus HA gene between the P and M genes or between
the HN and L genes as described previously (Durbin et
al., 2000). Another subclone used in assembly contained
the 3918-nt noncoding gene unit (GU3918) inserted be-
tween the HN and L genes, as described previously
(Skiadopoulos et al., 2000). Viruses with two or three ORF
insertions are designated with the first ORF inserted
between the N and P genes, the second ORF inserted
between the P and M genes, and the third additional
ORF, if any, inserted between the HN and L genes (Fig. 2).
Note that the HPIV2 HN gene insertion did not conform to
the rule of six in four of the five double- and triple-gene
insert antigenomes in which it was contained, due to the
error described above. However, in each case recombi-
nant virus was recovered. These cDNAs and their re-
spective viruses are indicated with asterisks. Corrected
(conforms to the rule of six) and uncorrected (does not
conform) versions of otherwise identical antigenome
plasmids containing HPIV1 and HPIV2 HN inserts were
used to derive r1HN2HN* (#6) and r1HN2HN (#7), re-
spectively (Fig. 2).
Recovery of viruses from cDNA and sequencing of
viral RNA (vRNA)
The full-length HPIV3 antigenomic cDNAs bearing sin-
gle or multiple ORFs of heterologous paramyxovirus pro-
tective antigens were recovered from HEp-2 cells by
transfection as described previously (Skiadopoulos et al.,
2000). rHPIV3s were then biologically cloned by plaque
purification on LLC-MK2 monolayers and were further
propagated on LLC-MK2 cells, as previously described
(Skiadopoulos et al., 1999a).
vRNA was isolated from biologically cloned recombi-
nant chimeric viruses as described previously (Skiado-
poulos et al., 1999a) and was used as the template for
reverse transcription and polymerase chain reaction (RT-
PCR) using oligonucleotide primers. The amplified prod-
ucts were analyzed by restriction endonuclease diges-
tion and DNA sequencing of the entire insert to deter-
mine the sequence of each supernumerary gene, as
previously described (Skiadopoulos et al., 1999a). In ad-
dition, the complete nucleotide sequence of two viruses
was determined, as previously described (Bailly et al.,
2000). In the case of complete genome sequence deter-
mination, the 3 and 5 ends of vRNA were sequenced by
3 and 5 RACE (Life Technologies), respectively, using
poly(A) polymerase and terminal transferase, respec-
tively (Bailly et al., 2000).
Replication of rHPIV3s in vitro
The mean peak titer of rHPIV3s was determined by
multicycle growth titrations. Each rHPIV3 tested was
inoculated in triplicate into LLC-MK2 monolayers in six-
well plates at a multiplicity of infection (m.o.i.) of 0.01, and
cultures were incubated at 32°C, as described previ-
ously (Tao et al., 1998). From each well 0.5 ml of medium
was harvested and replaced with 0.5 ml of fresh medium
at 0 h and at 5, 6, and 7 days postinfection. Virus present
in the samples was quantified by titration on LLC-MK2
monolayers in 96-well plates that were incubated for 7
days at 32°C. The titer (TCID50/ml) at 32 and 39°C was
determined by serial 10-fold dilutions of virus applied to
LLC-MK2 monolayer cultures on 96-well plates that were
incubated for 7 days, as described previously (Skiado-
poulos et al., 1999b). Virus was detected by hemadsorp-
tion and the mean peak virus titer, the highest titer
achieved on day 5, 6, or 7 is reported as log10 TCID50/ml
(50% tissue culture infectious dose/ml).
Immunofluorescence
Expression of the HPIV1, HPIV2, and measles virus
glycoproteins was confirmed by indirect immunofluores-
cence of LLC-MK2 cells infected with an rHPIV3 bearing
one or more foreign glycoprotein gene inserts. LLC-MK2
cells grown on glass slides were infected with virus, and
approximately 44 h postinfection the cells were fixed and
permeabilized as described previously (Skiadopoulos
and McBride, 1996). Mouse monoclonal anti-measles HA
antibodies (79-XV-V17, 80-III-B2, and 81-1-366; gift of Ste-
phen Jacobson, NIH; Durbin et al., 2000; and mouse
monoclonal anti-HPIV2 HN antibodies (1381, 1391, 1568,
and 1351; Rydbeck et al., 1988) were used to detect
measles virus HA and HPIV2 HN, respectively. Rabbit
polyclonal anti-HPIV1 antibodies were used to detect the
HPIV1 HN protein. The rabbit HPIV1 and HPIV2 antibod-
ies were obtained from fluid present in subcutaneous
chambers of rabbits immunized with purified virus as
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described previously (Clemons et al., 1992; Tao et al.,
2001). Fluorescein isothiocyanate conjugated goat anti-
mouse or donkey anti-rabbit IgG antibody (Jackson Im-
munochemicals, West Grove, PA) was used for indirect
immunofluorescence. Immunofluorescence was de-
tected and images were collected on a Leica TCS-SP2
(Leica Microsystems, Mannheim, Germany). Images
were processed using Leica TCS-NT/SP software (ver-
sion 1.6.587), Imaris 3.1.1 (Bitplane AG, Zurich Switzer-
land), and Adobe Photoshop 5.5 (Adobe systems).
Hemagglutination-inhibition assay
The presence of viral antigen in virions was deter-
mined using the hemagglutination-inhibition (HAI) assay
(van Wyke Coelingh et al., 1990) with the HPIV1 or HPIV2
rabbit antibodies described above or with HPIV3 poly-
clonal serum. The HPIV3 polyclonal serum antibodies
were obtained from a rhesus monkey infected several
times with HPIV3. The rhesus monkey was seronegative
to HPIV1 and HPIV2 prior to HPIV3 infection.
Neutralization assays
The susceptibility of recombinant viruses to neutral-
ization by HPIV antibodies was determined using two
distinct neutralization assays performed with heat-inac-
tivated rabbit or monkey polyclonal antibodies described
above or with a mixture of mouse monoclonal antibodies
to the HPIV3 HN (101/1 and 454/11) or HPIV3 F (c265,
c145, and a650; van Wyke Coelingh and Tierney, 1989). In
the first endpoint dilution neutralization assay, 100 TCID50
of virus was mixed with a dilution of antibody and was
incubated at 37°C for 1 h. The virus–antibody mixture
was then transferred to LLC-MK2 monolayers in 96-well
plates and incubated for 6 days at 32°C. The neutraliza-
tion titer is the highest dilution of antibody at which the
cultures were negative for infection, as determined by
hemadsorption with guinea pig erythrocytes.
The second neutralization assay was a virus titer re-
duction assay. One hundred microliters of medium con-
taining 106.3 TCID50 of virus was incubated with an equal
volume of a 1:20 dilution of HPIV1, HPIV3, or control
(dengue virus) polyclonal antibodies (gift of Stephen
Whitehead, NIH) for 1 h at 37°C. The virus–antibody
mixture was then titered by serial dilution on LLC-MK2
monolayers in 96-well plates, and the virus titer was
determined as described above.
Replication of recombinant and wild-type viruses in
hamsters
Four-week-old Golden Syrian hamsters (Charles River
Laboratories, NY), in groups of 6 to 8, which were sero-
negative for HPIV1, HPIV2, and HPIV3, were inoculated
intranasally (i.n.) with 0.1 ml L15 medium containing 106.0
TCID50 of virus. On day 4 postinfection, the lungs and
nasal turbinates were harvested, and the virus was
quantified by serial dilution of tissue homogenates on
LLC-MK2 monolayers, as previously described (Skiado-
poulos et al., 1998). The mean virus titer was calculated
for each group of hamsters and is expressed as log10
TCID50/g of tissue.
Immunogenicity and protective efficacy of recombinant
HPIV3s bearing single or multiple gene
inserts in hamsters
Hamsters in groups of 6 were inoculated i.n. with 0.1
ml medium containing 106.0 PFU of RSV (strain A2) or 106.0
TCID50 of a HPIV. Serum was collected 3 days before
infection and on day 28 after infection, and the titer of
serum HAI antibodies against HPIV3 or HPIV2 was de-
termined as described previously (van Wyke Coelingh et
al., 1985). The titer of serum-neutralizing antibodies di-
rected against HPIV1 or measles virus was determined
as described previously (Durbin et al., 2000; Tao et al.,
1999). On day 30 postinfection hamsters were chal-
lenged by i.n. administration of 106.0 TCID50 of HPIV1,
HPIV2, or rHPIV3 wt in a 0.1 ml inoculum. Nasal turbi-
nates and lungs were harvested 4 days later. The titer of
virus in the tissue homogenates was determined at 32°C
as described previously (Tao et al., 1998), and the viral
titers are expressed as mean log10 TCID50/g tissue.
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